P Castellucci

Summary

Publications

  1. pmc PET/CT in prostate cancer: non-choline radiopharmaceuticals
    P Castellucci
    Nuclear Medicine Unit, Policlinico S Orsola Malpighi, Bologna, Italy
    Q J Nucl Med Mol Imaging 56:367-74. 2012
  2. doi request reprint Diagnostic imaging work-up for disease relapse after radical treatment for prostate cancer: how to differentiate local from systemic disease? The urologist point of view
    R Schiavina
    Department of Urology, University of Bologna, Bologna, S Orsola Malpighi Hospital, Italy
    Rev Esp Med Nucl Imagen Mol 32:310-3. 2013
  3. ncbi request reprint Positron-emission tomography in imaging and staging prostate cancer
    M Farsad
    Nuclear Medicine PET Center, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Cancer Biomark 4:277-84. 2008
  4. ncbi request reprint The dilemma of localizing disease relapse after radical treatment for prostate cancer: which is the value of the actual imaging techniques?
    R Schiavina
    Department of Urology, University of Bologna, Bologna, S Orsola Malpighi Hospital, Italy
    Curr Radiopharm 6:92-5. 2013
  5. doi request reprint MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis: experience on seven patients
    E Derenzini
    Department of Haematology and Medical Oncology, University of Bologna, Bologna, Italy
    Ann Oncol 21:1173-8. 2010
  6. ncbi request reprint 18F-FDG PET/CT in the assessment of carcinoma of unknown primary origin
    V Ambrosini
    Unità Operativa di Medicina Nucleare, Padiglione 30, Policlinico S Orsola Malpighi, Via Massarenti 9, I 40138, Bologna, Italy
    Radiol Med 111:1146-55. 2006
  7. ncbi request reprint FDG PET and 90Y ibritumomab tiuxetan in patients with follicular lymphoma
    E Lopci
    S Orsola Malpighi Policlinic, Bologna, Italy
    Q J Nucl Med Mol Imaging 54:436-41. 2010
  8. ncbi request reprint [18F]FDG-PET/CT monitoring early identifies advanced ovarian cancer patients who will benefit from prolonged neo-adjuvant chemotherapy
    A A Martoni
    Unit of Medical Oncology, S Orsola Malpighi University Hospital, Bologna, Italy
    Q J Nucl Med Mol Imaging 55:81-90. 2011
  9. ncbi request reprint 18F-FDG PET/CT fusion imaging in paediatric solid extracranial tumours
    C Nanni
    Nuclear Medicine Department, PET CT Unit, Policlinico S Orsola Malpighi, Bologna, Italy
    Biomed Pharmacother 60:593-606. 2006
  10. ncbi request reprint Current status of PET imaging of neuroendocrine tumours ([18F]FDOPA, [68Ga]tracers, [11C]/[18F]-HTP)
    V Ambrosini
    Nuclear Medicine DIMES, University of Bologna and S Orsola Malpighi Hospital, Bologna, Italy
    Q J Nucl Med Mol Imaging 59:58-69. 2015

Collaborators

  • S Fanti
  • L Rampin
  • P L Zinzani
  • V Panebianco
  • F Montorsi
  • L Landuzzi
  • M A Pantaleo
  • A Bernardi
  • C Nanni
  • G Biasco
  • M Gacci
  • H Jadvar
  • D Santini
  • R Schiavina
  • G Martorana
  • V Ambrosini
  • E Lopci
  • E Brunocilla
  • M Farsad
  • M Borghesi
  • M Picchio
  • F Ceci
  • V Vagnoni
  • A A Martoni
  • E Derenzini
  • V Stefoni
  • A D'Errico Grigioni
  • D Rubello
  • R Franchi
  • F Manferrari
  • A Bertaccini
  • R Canini
  • A Briganti
  • G Gandaglia
  • J J Morigi
  • F Barchetti
  • E Incerti
  • P Mapelli
  • L Gianolli
  • M Kirienko
  • M Rosati
  • A Musto
  • S Quercia
  • L Ricci Maccarini
  • C Zamagni
  • P de Iaco
  • G Montini
  • C Agostinelli
  • S Pileri
  • C Pellegrini
  • A Broccoli
  • F Venturini
  • A M Maffione
  • M Baccarani
  • C Fonti
  • M P Fina
  • M Tani
  • I Santi
  • L Gandolfi
  • M Garofalo
  • C Rocca
  • F Sanguedolce
  • A Franceschelli
  • S Concetti
  • A Moretti
  • G Fiorentini
  • E Salizzoni
  • B Corti
  • G Battista
  • W F Grigioni

Detail Information

Publications14

  1. pmc PET/CT in prostate cancer: non-choline radiopharmaceuticals
    P Castellucci
    Nuclear Medicine Unit, Policlinico S Orsola Malpighi, Bologna, Italy
    Q J Nucl Med Mol Imaging 56:367-74. 2012
    ....
  2. doi request reprint Diagnostic imaging work-up for disease relapse after radical treatment for prostate cancer: how to differentiate local from systemic disease? The urologist point of view
    R Schiavina
    Department of Urology, University of Bologna, Bologna, S Orsola Malpighi Hospital, Italy
    Rev Esp Med Nucl Imagen Mol 32:310-3. 2013
    ..Low sensitivity, costs, availability of technologies and confirmation of the results remain the major limitations in most cases...
  3. ncbi request reprint Positron-emission tomography in imaging and staging prostate cancer
    M Farsad
    Nuclear Medicine PET Center, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Cancer Biomark 4:277-84. 2008
    ..At present, the only clinical indication for imaging PCa with 11C-choline-PET is evaluation of suspected recurrence after treatment...
  4. ncbi request reprint The dilemma of localizing disease relapse after radical treatment for prostate cancer: which is the value of the actual imaging techniques?
    R Schiavina
    Department of Urology, University of Bologna, Bologna, S Orsola Malpighi Hospital, Italy
    Curr Radiopharm 6:92-5. 2013
    ..The aim of the present paper is to evaluate the management of patients with BCR after radical treatment of PCa from the urologist point of view. ..
  5. doi request reprint MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis: experience on seven patients
    E Derenzini
    Department of Haematology and Medical Oncology, University of Bologna, Bologna, Italy
    Ann Oncol 21:1173-8. 2010
    ..Adult Langerhans cell histiocytosis (LCH) is a rare disease. The combination of vinblastine and prednisone, given in a 6-month course, is the standard of care but prospective randomized trials are lacking...
  6. ncbi request reprint 18F-FDG PET/CT in the assessment of carcinoma of unknown primary origin
    V Ambrosini
    Unità Operativa di Medicina Nucleare, Padiglione 30, Policlinico S Orsola Malpighi, Via Massarenti 9, I 40138, Bologna, Italy
    Radiol Med 111:1146-55. 2006
    ..The aim of this study was to assess the role of 18F-fluorodeoxyglucose (FDG) PET/computed tomography (CT) in the identification of occult primary cancers...
  7. ncbi request reprint FDG PET and 90Y ibritumomab tiuxetan in patients with follicular lymphoma
    E Lopci
    S Orsola Malpighi Policlinic, Bologna, Italy
    Q J Nucl Med Mol Imaging 54:436-41. 2010
    ..In this paper we investigate its value in patients affected by follicular lymphoma (FL) before and after treatment with [90Y]Ibritumomab Tiuxetan (Zevalin(R))...
  8. ncbi request reprint [18F]FDG-PET/CT monitoring early identifies advanced ovarian cancer patients who will benefit from prolonged neo-adjuvant chemotherapy
    A A Martoni
    Unit of Medical Oncology, S Orsola Malpighi University Hospital, Bologna, Italy
    Q J Nucl Med Mol Imaging 55:81-90. 2011
    ..However a percentage of patients could benefit from additional courses. [(18)F]FDG-PET/CT monitoring during na-CHT could predict early pathological response and allow the delivery of an optimal na-CHT duration...
  9. ncbi request reprint 18F-FDG PET/CT fusion imaging in paediatric solid extracranial tumours
    C Nanni
    Nuclear Medicine Department, PET CT Unit, Policlinico S Orsola Malpighi, Bologna, Italy
    Biomed Pharmacother 60:593-606. 2006
    ..It will also discuss the physiologic biodistribution of 18F-FDG, outlining the normal variants in the paediatric patients that may lead to misinterpretation...
  10. ncbi request reprint Current status of PET imaging of neuroendocrine tumours ([18F]FDOPA, [68Ga]tracers, [11C]/[18F]-HTP)
    V Ambrosini
    Nuclear Medicine DIMES, University of Bologna and S Orsola Malpighi Hospital, Bologna, Italy
    Q J Nucl Med Mol Imaging 59:58-69. 2015
    ..This review aims to provide an overview of the current status and clinical application of PET tracers to image well differentiated NEN and to focus on the still open-issues of debate. ..
  11. doi request reprint A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients
    P L Zinzani
    Institute of Hematology and Medical Oncology L and A Seragnoli, University of Bologna, Bologna, Italy
    Ann Oncol 19:769-73. 2008
    ....
  12. pmc Advances in preclinical therapeutics development using small animal imaging and molecular analyses: the gastrointestinal stromal tumors model
    M A Pantaleo
    Department of Hematology and Oncology Sciences L A Seragnoli, Sant Orsola Malpighi Hospital, University of Bologna, 40138, Bologna, Italy
    Clin Exp Med 9:199-205. 2009
    ..This approach of cancer research on GISTs is crucial and essential for innovative perspectives that could cross over to other types of cancer...
  13. doi request reprint Imaging biomarkers in prostate cancer: role of PET/CT and MRI
    M Picchio
    Nuclear Medicine Unit, IRCCS San Raffaele Scientific Institute, Via Olgettina 60, 20132, Milan, Italy
    Eur J Nucl Med Mol Imaging 42:644-55. 2015
    ..Innovative imaging strategies including new radiotracers and hybrid scanners such as PET/MRI are also discussed. ..
  14. ncbi request reprint 11C-choline positron emission tomography/computerized tomography for tumor localization of primary prostate cancer in comparison with 12-core biopsy
    G Martorana
    Department of Urology, Pathology Division, Policlinico S Orsola Malpighi, University of Bologna, Viale Palagi 9, Bologna, Italy
    J Urol 176:954-60; discussion 960. 2006
    ....